Beijing Anzhen Hospital
303
67
74
59
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
1.0%
3 terminated/withdrawn out of 303 trials
95.2%
+8.7% vs industry average
13%
38 trials in Phase 3/4
8%
5 of 59 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (303)
STudy of Aspirin Removal in Patients Supported by the Fully Magnetically Levitated CH-VAD Pump
Role: collaborator
Cohort Study of Postoperative Cognitive Dysfunction After Off-Pump Coronary Artery Bypass Grafting
Role: lead
Real-World Study of Woven EndoBridge for Intracranial Aneurysm Treatment
Role: collaborator
Target-directed Management of Cerebral Oxygenation in Patients After Receiving ECPR
Role: collaborator
Prospective Study on the Effectiveness and Safety of Bi-polar Pulse-field Tip-catheter Ablation for Atrial Fibrillation in China（POTENTIAL-AF）
Role: lead
Effectiveness of Patch-Electrocardiogram Recorders in Screening for Atrial Fibrillation in Elderly People in the Chinese Community
Role: lead
Complex Arrhythmia Registry
Role: lead
All-Trans Retinoic Acid for the Treatment of Hemophagocytic Lymphohistiocytosis
Role: lead
China Antihypertensive Trial for Intracranial Aneurysm
Role: collaborator
Correlation and Prognostic Value of Body Composition, Cardiac Structure and Function in Patients With Different Heart Failure Subtypes
Role: lead
AI-Guided Intensified Follow-up After Surgery for Acute Type A Aortic Dissection
Role: collaborator
Effect of Guanxinning Tablet on Coronary Microcirculation After Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction
Role: lead
Effect of the Traditional Chinese Medicine Yufeng Ningxin in Patients With Hypertension
Role: lead
Target-Oriented Strategy of Ultra-Low LDL-C (<1.0 vs. 1.0-1.39 mmol/L) in Extreme-High-Risk ASCVD Patients: Clinical Benefit, Safety and Cost-Effectiveness Assessment
Role: lead
Active Post-Market Surveillance of Innovative Devices for Valvular Heart Disease
Role: lead
Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery
Role: collaborator
Smartwatch-based Intervention for Cardiovascular Health (SWITCH)
Role: lead
Standby Cannulated ECMO for High-Risk Percutaneous Coronary Intervention
Role: lead
Artificial Intelligence for Ulinastatin Responder Outcome & Risk Assessment in CPB
Role: lead
Prediction of LVAR and MACE in STEMI Though Plasma Multiomics Analysis
Role: lead